Literature DB >> 19116625

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

Véronique Baud1, Michael Karin.   

Abstract

Nuclear factor kappaB (NF-kappaB) transcription factors have a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-kappaB and the signalling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemotherapy and radiotherapy. This article discusses recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-kappaB in human cancer, particularly in multiple myeloma. The therapeutic potential and benefit of targeting NF-kappaB in cancer, and the possible complications and pitfalls of such an approach, are explored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19116625      PMCID: PMC2729321          DOI: 10.1038/nrd2781

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  102 in total

1.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

2.  Two pathways to NF-kappaB.

Authors:  Joel L Pomerantz; David Baltimore
Journal:  Mol Cell       Date:  2002-10       Impact factor: 17.970

Review 3.  The IKK NF-kappa B system: a treasure trove for drug development.

Authors:  Michael Karin; Yumi Yamamoto; Q May Wang
Journal:  Nat Rev Drug Discov       Date:  2004-01       Impact factor: 84.694

4.  RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100.

Authors:  Emmanuel Derudder; Emmanuel Dejardin; Linda L Pritchard; Douglas R Green; Marie Korner; Veronique Baud
Journal:  J Biol Chem       Date:  2003-04-21       Impact factor: 5.157

5.  Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells.

Authors:  Terry H Landowski; Nancy E Olashaw; Deepak Agrawal; William S Dalton
Journal:  Oncogene       Date:  2003-04-24       Impact factor: 9.867

6.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation.

Authors:  Robert Lucito; John Healy; Joan Alexander; Andrew Reiner; Diane Esposito; Maoyen Chi; Linda Rodgers; Amy Brady; Jonathan Sebat; Jennifer Troge; Joseph A West; Seth Rostan; Ken C Q Nguyen; Scott Powers; Kenneth Q Ye; Adam Olshen; Ennapadam Venkatraman; Larry Norton; Michael Wigler
Journal:  Genome Res       Date:  2003-09-15       Impact factor: 9.043

7.  Characterizing the cancer genome in lung adenocarcinoma.

Authors:  Barbara A Weir; Michele S Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M Lin; Michael A Province; Aldi Kraja; Laura A Johnson; Kinjal Shah; Mitsuo Sato; Roman K Thomas; Justine A Barletta; Ingrid B Borecki; Stephen Broderick; Andrew C Chang; Derek Y Chiang; Lucian R Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F Gazdar; Thomas Giordano; Heidi Greulich; Megan Hanna; Bruce E Johnson; Mark G Kris; Alex Lash; Ling Lin; Neal Lindeman; Elaine R Mardis; John D McPherson; John D Minna; Margaret B Morgan; Mark Nadel; Mark B Orringer; John R Osborne; Brad Ozenberger; Alex H Ramos; James Robinson; Jack A Roth; Valerie Rusch; Hidefumi Sasaki; Frances Shepherd; Carrie Sougnez; Margaret R Spitz; Ming-Sound Tsao; David Twomey; Roel G W Verhaak; George M Weinstock; David A Wheeler; Wendy Winckler; Akihiko Yoshizawa; Soyoung Yu; Maureen F Zakowski; Qunyuan Zhang; David G Beer; Ignacio I Wistuba; Mark A Watson; Levi A Garraway; Marc Ladanyi; William D Travis; William Pao; Mark A Rubin; Stacey B Gabriel; Richard A Gibbs; Harold E Varmus; Richard K Wilson; Eric S Lander; Matthew Meyerson
Journal:  Nature       Date:  2007-11-04       Impact factor: 49.962

8.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity.

Authors:  Aaron D Schimmer; Kate Welsh; Clemencia Pinilla; Zhiliang Wang; Maryla Krajewska; Marie-Josee Bonneau; Irene M Pedersen; Shinichi Kitada; Fiona L Scott; Beatrice Bailly-Maitre; Gennadi Glinsky; Dominick Scudiero; Edward Sausville; Guy Salvesen; Adel Nefzi; John M Ostresh; Richard A Houghten; John C Reed
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

9.  Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.

Authors:  Yun Dai; Xin-Yan Pei; Mohamed Rahmani; Daniel H Conrad; Paul Dent; Steven Grant
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

Review 10.  Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery.

Authors:  Ezra Burstein; Colin S Duckett
Journal:  Curr Opin Cell Biol       Date:  2003-12       Impact factor: 8.382

View more
  442 in total

1.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Targeting MYC dependence in cancer by inhibiting BET bromodomains.

Authors:  Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

Review 3.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

4.  Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins.

Authors:  Akiko Takeda; Nayan J Sarma; Anmaar M Abdul-Nabi; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2010-03-16       Impact factor: 5.157

Review 5.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

6.  IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ.

Authors:  Li-Chung Hsu; Thomas Enzler; Jun Seita; Anjuli M Timmer; Chih-Yuan Lee; Ting-Yu Lai; Guann-Yi Yu; Liang-Chuan Lai; Vladislav Temkin; Ursula Sinzig; Thiha Aung; Victor Nizet; Irving L Weissman; Michael Karin
Journal:  Nat Immunol       Date:  2010-12-19       Impact factor: 25.606

Review 7.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

8.  Betulinic acid inhibits endotoxin-stimulated phosphorylation cascade and pro-inflammatory prostaglandin E(2) production in human peripheral blood mononuclear cells.

Authors:  Vijayan Viji; Antony Helen; Varma R Luxmi
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

9.  Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.

Authors:  Ivana Pilchova; Katarina Klacanova; Katarina Dibdiakova; Simona Saksonova; Andrea Stefanikova; Eva Vidomanova; Lucia Lichardusova; Jozef Hatok; Peter Racay
Journal:  Neurochem Res       Date:  2017-07-19       Impact factor: 3.996

10.  Nuclear factor-κB activation in primary lymphoma of bone.

Authors:  Lianne Koens; Fenna H Heyning; Agota Szepesi; András Matolcsy; Pancras C W Hogendoorn; Patty M Jansen
Journal:  Virchows Arch       Date:  2013-01-19       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.